In a few short years, excitement about groundbreaking anti-obesity drugs made Novo Nordisk Europe’s most highly valued company and Eli Lilly the biggest pharma group in the world. Just as quickly, investors are losing their appetite for the trade.
短短几年間，圍繞突破性抗肥胖藥物的興奮就讓諾和諾德(Novo Nordisk)成爲歐洲估值最高的公司，讓禮來(Eli Lilly)成爲全球最大的製藥集團。但在同樣迅速的時間內，投資者就對這一交易失去了興趣。
您已閱讀4%（350字），剩餘96%（9005字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。